Every 8-K that Cue Biopharma Inc (CUE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CUE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CUE filings page.
Cue Biopharma, Inc. reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million a year earlier, driven by a preclinical milestone under its Boehringer Ingelheim collaboration. The company highlighted recent submission of an IND to the FDA for CUE-221 in food allergy and expects Phase 2 data in chronic spontaneous urticaria by the end of the third quarter of 2026. CUE-401 is expected to enter a Phase 1 study with an IND filing anticipated by year-end 2026.
Operating expenses rose sharply due to one-time items: research and development expenses were $49.0 million and general and administrative expenses were $46.6 million, reflecting approximately $20.0 million of CUE-221-related cash payments and $20.0 million of warrant fair-value expense, plus about $23.0 million of strategic transformation costs and $19.7 million of non-cash stock-based compensation. A net non-cash loss of $63.1 million related to liability-classified warrants contributed to a net loss of $153.1 million, versus $8.5 million in 2025. Cash and cash equivalents were $17.4 million as of June 30, 2026, and the company subsequently completed a $50 million private placement. Leadership was expanded with a new Chief Medical Officer and Head of R&D and a new Chief Financial Officer.
Cue Biopharma, Inc. appointed James Ahlers as Chief Financial Officer and principal financial officer, effective July 30, 2026, under an executive employment agreement. Ahlers, age 62, brings extensive biotech finance experience, including prior roles at Intarcia Therapeutics, RenovoRx, Titan Pharmaceuticals and other life sciences companies.
The agreement provides a $450,000 annual base salary and an annual incentive bonus targeted at up to 45% of base salary. On the effective date, he received inducement equity grants under the 2026 Inducement Stock Incentive Plan: nonstatutory stock options to purchase 51,00 shares at an exercise price of $30.40 per share and a restricted stock unit award for 25,500 shares, vesting quarterly over four years. Upon certain qualifying terminations, including in connection with a change in control, he is eligible for cash severance, continued COBRA premium payments for up to nine months, and accelerated vesting of equity awards, subject to customary release and other conditions.
Cue Biopharma, Inc. entered into a private placement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to raise gross proceeds of approximately $50.0 million. The transaction covers 1,418,071 shares of common stock at $33.21 per share and pre-funded warrants to purchase up to 87,500 shares at $33.209 per warrant.
The pre-funded warrants are immediately exercisable at $0.001 per share on a cashless basis and include beneficial ownership limits of 4.99% or 9.99%, which can increase up to 19.99% with notice. Cue plans to use net proceeds to fund clinical development and for general corporate purposes. The closing is expected on July 13, 2026, subject to customary conditions, and the company agreed to register the resale of the securities within 30 days of closing.
Separately, under its 2026 Stock Incentive Plan, Cue granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao‑Lee Lin, 109,178 to the Chief Legal and Compliance Officer, and 81,884 to the Principal Accounting Officer, plus 21,800 RSUs to each non‑employee director.
Cue Biopharma, Inc. reported results of a special stockholder meeting held on June 1, 2026. Stockholders approved the issuance of common shares upon exercise of warrants issued in May 2026 in connection with a licensing transaction and related private placement, satisfying Nasdaq Listing Rule 5635(a), (c) and (d).
They also approved the company’s 2026 Stock Incentive Plan, which will govern future equity awards to employees and other eligible participants. A proposal to allow adjournment of the meeting, if needed, was approved but ultimately not required because the main proposals received sufficient support.
Cue Biopharma, Inc. reported significant governance and leadership changes. On May 29, 2026, four directors — Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen — resigned from the Board and its committees, with the company stating their decisions were not due to any disagreement over operations, policies or practices.
Effective June 1, 2026, the Board appointed Sumita Ray as Chief Legal & Compliance Officer and Corporate Secretary, succeeding Colin Sandercock, who continues as Senior Vice President, Intellectual Property. The Board also named Michael Meluzio Vice President, Principal Accounting Officer, elevating him from his prior finance role without additional compensation.
On May 30, 2026, the Board appointed Daniel Camardo and Viola Meehan as directors for one-year terms and reduced the Board size from seven to five directors effective June 1, 2026. Camardo and Meehan were assigned key committee roles, including committee chair positions, and will receive cash and equity compensation under the existing Director Compensation Policy and enter into the company’s standard indemnification agreements.
Cue Biopharma reported first quarter 2026 results that show sharply higher collaboration revenue and a reduced net loss, alongside important strategic and financing steps. Revenue for the quarter rose to $5.7 million from $0.4 million a year earlier, mainly from its Boehringer Ingelheim collaboration. Research and development expenses declined to $6.9 million from $8.5 million, while general and administrative costs were stable at about $4.2 million. Net loss narrowed to $5.2 million from $12.3 million, and the company reported $16.4 million in cash and cash equivalents as of March 31, 2026.
After quarter-end, Cue Biopharma completed a $30 million private placement, yielding approximately $28 million in net proceeds, and received a $7.5 million preclinical milestone payment from Boehringer Ingelheim, strengthening near-term funding. Strategically, the company licensed CUE-221, a Phase 2 anti-IgE program for allergic disease, advanced CUE-401 toward Phase 1 for autoimmune conditions, and appointed Shao-Lee Lin, M.D., Ph.D., as President and CEO to lead its transition as a clinical-stage company.
Cue Biopharma entered an exclusive license with Ascendant Health Sciences for Ascendant-221, a Phase 2 anti-IgE antibody, granting global rights outside Greater China. Cue will pay a $15 million upfront fee, up to $676.5 million in development, regulatory and commercial milestones, plus tiered royalties on net sales.
As partial consideration, Ascendant receives pre-funded warrants to buy 551,724 Cue shares at $0.001 per share and may be topped up to at least 7.5% beneficial ownership upon achieving specified milestones, subject to Nasdaq stockholder approvals and ownership caps. A related investor agreement adds lock-up, standstill and voting commitments.
Cue also agreed to a private placement of pre-funded warrants for up to 2,727,272 shares and accompanying warrants for up to 1,363,636 shares at $11.00, targeting roughly $30 million in gross proceeds to support the pipeline and Ascendant-221. The board adopted a 2026 Inducement Stock Incentive Plan covering 3,000,000 shares.
Dr. Shao-Lee Lin was appointed President and CEO with a $660,000 base salary, a target bonus of 55% of salary, an inducement option for 655,074 shares and 327,537 RSUs, with potential top-up equity to about 8.5% fully diluted ownership. Former interim CEO Lucinda Warren receives cash severance of $474,010.27, COBRA support and full vesting of time-based equity under a separation agreement.
Cue Biopharma, Inc. approved a 1-for-30 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026. The move is intended, among other things, to help the company meet the Nasdaq Capital Market’s minimum bid price requirement.
Every thirty issued and outstanding shares of common stock will be reclassified into one share, with stockholders receiving cash instead of fractional shares. The number of authorized shares and the $0.001 par value will remain unchanged. Outstanding options, warrants and equity plan share reserves will be proportionately adjusted, and post-split trading under the “CUE” symbol is expected to begin on April 24, 2026.
Cue Biopharma, Inc. held its 2026 annual meeting, where stockholders elected six directors and ratified the company’s independent auditor. A non-binding advisory proposal on executive compensation was also approved.
Stockholders further approved an amendment authorizing a reverse stock split of common stock at a ratio between 1-for-30 and 1-for-50, with the exact ratio and timing left to the Board’s sole discretion without further stockholder approval.
Cue Biopharma, Inc. reports that partner Boehringer Ingelheim has selected its first compound for lead optimization under their April 2025 collaboration focused on differentiated B cell depletion molecules, including Cue’s CUE-501 candidate. This preclinical milestone triggers a $7.5 million payment to Cue Biopharma, which is expected in May 2026.
The company notes that, despite this milestone, it continues to face risks typical for an early-stage biotech, including limited operating history, limited cash, a history of losses, and a current going concern determination about its ability to fund operations beyond the next twelve months.
Cue Biopharma announced a leadership change, appointing Chief Financial and Business Officer Lucinda Warren as Interim President and Chief Executive Officer effective March 27, 2026. She will also retain her finance and business responsibilities and receives a base salary of $525,000 plus a $10,000 monthly interim supplement.
Warren is eligible for an annual bonus up to 45% of base salary and a future stock option equal to about 1.0% of outstanding shares upon achieving a financing milestone. Former CEO Usman Azam resigned on March 26, 2026 and will receive cash severance of $232,500 and up to 12 months of COBRA premium payments under a separation agreement.
Cue Biopharma reported significantly higher collaboration revenue for 2025, driven by a new strategic collaboration and license agreement with ImmunoScape. Collaboration revenue rose to $21.9 million in the fourth quarter from $1.6 million a year earlier and to $27.5 million for the full year from $9.3 million in 2024, leading to fourth quarter net income of $1.6 million and a reduced full-year net loss of $26.6 million compared with $40.7 million in 2024.
The ImmunoScape agreement provides total upfront payments of $15 million, of which Cue received $9.5 million (net of withholding taxes) in the fourth quarter of 2025 and is entitled to an additional $5 million in November 2026, plus a 40% equity stake and eligibility for high-single digit royalties. The company advanced its lead autoimmune candidate CUE-401 toward IND readiness, reporting preclinical toxicology and pharmacology data in which CUE-401 was well tolerated with no adverse events observed and presenting supportive in vivo and in vitro data at a major immune regulation meeting. As of December 31, 2025, Cue Biopharma had $27.1 million in cash and cash equivalents, while continuing to operate at a full-year loss.
Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026. The company explains how stockholders can submit proposals or director nominations for that meeting and the deadlines that apply.
Stockholder proposals intended for inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at Cue Biopharma’s Boston headquarters by February 28, 2026, which the company considers a reasonable time before it begins printing and mailing proxy materials. For other business or director nominations to be brought directly before the meeting under the company’s Amended and Restated Bylaws, notice must also be received by February 28, 2026, or the later of 90 days before the meeting and 10 days after public announcement of the meeting date.
The company notes that stockholders who plan to solicit proxies in favor of their own director nominees, rather than the company’s nominees, and who seek to comply with the SEC’s universal proxy rule (Rule 14a-19), must likewise provide the required notice by February 28, 2026. If a stockholder misses these deadlines, the board’s named proxies may exercise discretionary voting authority on that stockholder’s proposal at the 2026 Annual Meeting.
Cue Biopharma appointed Lucinda WarrenChief Financial and Business Officer
Warren has over 30 years of global experience in pharmaceuticals and biotechnology, including a decade in business development roles at Johnson & Johnson and leadership positions at Janssen organizations. She receives no additional compensation for these new responsibilities, her employment terms remain unchanged, and there are no related-party or family relationships tied to her appointment.
Cue Biopharma, Inc. reported that on November 24, 2025 it made an updated corporate presentation publicly available on its website and furnished that presentation as Exhibit 99.1 to a Form 8-K. The company notes that the materials provided under Item 7.01, including the presentation, are being furnished rather than filed under the Exchange Act, which means they are not subject to certain liabilities associated with filed reports and are not automatically incorporated into other securities filings unless specifically referenced.
Cue Biopharma, Inc. (CUE) announced that Chief Medical Officer Matteo Levisetti will leave the company, with his employment ending on November 28, 2025. The company and Dr. Levisetti agreed to his separation on November 17, 2025.
Subject to signing and not revoking a separation and release of claims agreement, Dr. Levisetti will receive a lump-sum cash severance of $556,837.60, equal to nine months of base salary plus a prorated portion of his 2025 target bonus, paid in the first regular payroll cycle after the separation agreement becomes effective. If he elects COBRA coverage, Cue Biopharma will pay the full premiums for up to nine months after the Separation Date, or until he secures reasonably comparable new coverage or COBRA otherwise ends.
Cue Biopharma (CUE) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The release is furnished as Exhibit 99.1.
The company notes that the information in this report, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as expressly set forth by specific reference.
Cue Biopharma (CUE) announced a Collaboration and License Agreement with ImmunoScape Pte. Ltd. (IMSCP), following IMSCP’s exercise of an option on November 6, 2025 to license the company’s CUE-100 Series, including CUE-101 and CUE-102, for all oncology indications, subject to certain exclusions.
The structure grants IMSCP a co-exclusive development license for five years or longer (while a specified number of CUE‑100 Series molecules remain under active development), with Cue retaining non‑exclusive research rights to support other programs. IMSCP also receives an exclusive commercial license for any CUE‑100 Series molecule it advances to IND‑enabling studies during the co‑exclusive period.
Cue received $5 million in Q4 2025 tied to the option and its exercise, and is entitled to 40% of IMSCP’s issued and outstanding equity plus warrants upon specified dilution events. Additional time‑based payments include $5 million in or prior to December 2025 and $5 million before the first anniversary of option exercise, along with high single‑digit royalties on global net sales and low‑ to mid‑double digit royalties from sublicensing. IMSCP may terminate the agreement on 60 days’ written notice.
Cue Biopharma is making a planned leadership transition, appointing Usman Azam as President and Chief Executive Officer and a director effective September 29, 2025, as longtime CEO Daniel R. Passeri retires from the role and the board but continues as a strategic advisor.
Under his employment agreement, Dr. Azam will receive a $620,000 annual base salary, a target bonus of up to 50% of base salary, and stock options for 1,875,000 time-based shares plus 375,000 performance-based shares that vest in full if a specified financing milestone is achieved. If he is terminated without cause or resigns for good reason, he is eligible for cash severance equal to 12 months of base salary plus a prorated target bonus and up to 12 months of COBRA premium payments.
Through a separation agreement, Mr. Passeri will receive a lump-sum cash payment of $838,750, up to 18 months of COBRA premiums, and a 12‑month acceleration of vesting and extended exercisability of his existing equity awards. An advisor agreement running to March 30, 2026 grants him an additional option for 375,000 shares that vests if the same financing milestone is met while his existing awards continue to vest during his advisory term.
Cue Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 to this Current Report and the company states that the information is being "furnished" rather than "filed," so it is not subject to the liability provisions of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference. The registrant’s common stock trades on the Nasdaq Capital Market under the symbol CUE.